Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mahadevan

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Nature Cancer|September 22, 2022
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypesSatyaki Sengupta, Sanjukta Das, Angela C Crespo, et al.
Cancer Cell|September 23, 2022
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerShunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, et al.
The Journal of Clinical Investigation|November 5, 2020
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockadeKartik Sehgal, Andrew Portell, Elena V Ivanova, et al.
Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.
Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Cancer Immunology Research|September 8, 2025
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J Brea, Simon Baldacci, Neil Savage, et al.
Cancer Discovery|August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapySimon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Nature Cancer|September 22, 2022
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypesSatyaki Sengupta, Sanjukta Das, Angela C Crespo, et al.
Cancer Cell|September 23, 2022
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerShunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, et al.
The Journal of Clinical Investigation|November 5, 2020
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockadeKartik Sehgal, Andrew Portell, Elena V Ivanova, et al.
Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.
Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Cancer Immunology Research|September 8, 2025
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J Brea, Simon Baldacci, Neil Savage, et al.
Cancer Discovery|August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapySimon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Pageof 14